Abstract:Pulmonary hypertension (PH) is a life‐threatening cardiovascular disease with limited treatment options. Nanozymes hold potential for PH treatment, but existing nanozymes are all metallic, raising safety concerns. In this study, a non‐metallic nanozyme, melanin‐PVP‐PEG (MPP) is reported, which effectively alleviates monocrotaline‐induced PH, primarily by inhibiting ROS‐TGF‐β1 signaling. Pulmonary hypertension (PH) is a life‐threatening cardiovascular disease with a lack of effective treatment options. Nanozymes, though promising for PH therapy, pose safety risks due to their metallic nature. Here, a non‐metallic nanozyme is reported for the treatment of monocrotaline (MCT)‐induced PH with a therapeutic mechanism involving the ROS/TGF‐β1 signaling. The synthesized melanin‐polyvinylpyrrolidone‐polyethylene glycol (MPP) nanoparticles showcase ultra‐small size, excellent water solubility, high biocompatibility, and remarkable antioxidant capacity. The MPP nanoparticles are capable of effectively eliminating ROS in isolated pulmonary artery smooth muscle cells (PASMCs) from PH rats, and significantly reduce PASMC proliferation and migration. In vivo results from a PH model demonstrate that MPP nanoparticles significantly increase pulmonary artery acceleration time, decrease wall thickening and PCNA expression in lung tissues, as evidenced by echocardiograpy, histology and immunoblot analysis. Additionally, MPP nanoparticles treatment improve running capacity, decrease Fulton index, and attenuate right ventricular fibrosis in MCT‐PH rats by using treadmill test, picrosirius red, and trichrome Masson staining. Further transcriptomic and biochemical analyses reveal that inhibiting ROS‐driven activation of TGF‐β1 in the PA is the mechanism by which MPP nanoparticles exert their therapeutic effect. This study provides a novel approach for treating PH with non‐metallic nanozymes based on a well‐understood mechanism.

Cocrystal Pleomorphism-Inspired Drug Nanoassembly for Pulmonary-Endothelium Targeting and Pulmonary Hypertension Treatment

Alleviating experimental pulmonary hypertension<i> via</i> co-delivering FoxO1 stimulus and apoptosis activator to hyperproliferating pulmonary arteries

Active Anchoring Stimuli-Responsive Nano-Craft to Relieve Pulmonary Vasoconstriction by Targeting Smooth Muscle Cell for Hypoxic Pulmonary Hypertension Treatment

CeO2/Bovine Serum Albumin Nanoclusters with Robust Reactive Oxygen Species Scavenging and Improved Endothelial Dysfunction Abilities for the Treatment of Pulmonary Hypertension

Anti-inflammatory Drug-Assisted Microrna Gene Therapy for Effectively Improving Pulmonary Hemodynamics

Targeted Delivery of Sildenafil for Inhibiting Pulmonary Vascular Remodeling

Natural Targeting Potent ROS‐eliminating Tungsten‐based Polyoxometalate Nanodots for Efficient Treatment of Pulmonary Hypertension

Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension

DYZY01 alleviates pulmonary hypertension via inhibiting endothelial cell pyroptosis and rescuing endothelial dysfunction

Pulmonary arterial hypertension nanotherapeutics: New pharmacological targets and drug delivery strategies

Targeting ADORA-PDE10 cAMP Microdomain: A Novel Therapeutic Approach for Pulmonary Hypertension

Discovery of Novel Pyrazolo[3,4- b ] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension

Discovery and Optimization of Hsp110 and sGC Dual-Target Regulators for the Treatment of Pulmonary Arterial Hypertension

Homology modeling, molecular dynamics and virtual screening of endothelin-A receptor for the treatment of pulmonary arterial hypertension

Bioactive Compounds From Coptidis Rhizoma Alleviate Pulmonary Arterial Hypertension by Inhibiting Pulmonary Artery Smooth Muscle Cells' Proliferation and Migration

Nanoparticle delivery of VEGF and SDF‐1α as an approach for treatment of pulmonary arterial hypertension

Targeted delivery of baicalein-p53 complex to smooth muscle cells reverses pulmonary hypertension

The Novel Lysosomal Autophagy Inhibitor (ROC-325) Ameliorates Experimental Pulmonary Hypertension

A Non‐Metallic Nanozyme Ameliorates Pulmonary Hypertension Through Inhibiting ROS/TGF‐β1 Signaling

Nanocrystals based pulmonary inhalation delivery system: advance and challenge

Spatial Targeting of Fibrosis-Promoting Macrophages with Nanoscale Metal-Organic Frameworks for Idiopathic Pulmonary Fibrosis Therapy.